Literature DB >> 16082224

p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1.

Stefano Salvioli1, Massimiliano Bonafé, Cristiana Barbi, Gianluca Storci, Chiara Trapassi, Francesca Tocco, Silvia Gravina, Matteo Rossi, Luca Tiberi, Chiara Mondello, Daniela Monti, Claudio Franceschi.   

Abstract

A common polymorphism at codon 72 in p53 gene leads to an arginine to proline aminoacidic substitution which affects in an age-dependent manner the susceptibility of cells to undergo apoptosis after oxidative stress. Here we report that dermal fibroblasts from Proline allele carriers (Pro+) display a higher expression of p21WAF1 gene, in both basal conditions and after treatment with doxorubicin or camptothecin. This phenomenon is accompanied by a lower susceptibility of Pro+ cells to undergo apoptosis, a lower capability to over cross G1-S transition and an increased propensity to express markers of cell senescence, with respect to fibroblasts from Arginine homozygotes (Pro-). All these phenomena are particularly evident in cells from centenarians. We conclude that the functional difference between the two p53 codon 72 alleles exerts a broad impact on the capability of cell from aged people to respond to stressors such as cytotoxic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082224     DOI: 10.4161/cc.4.9.1978

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  18 in total

Review 1.  The role of p53 gene family in reproduction.

Authors:  Wenwei Hu
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

2.  Functional analysis of the p53 codon 72 polymorphism in black South Africans with rheumatoid arthritis--a pilot study.

Authors:  Devapregasan Moodley; Girish M Mody; Anil A Chuturgoon
Journal:  Clin Rheumatol       Date:  2010-06-10       Impact factor: 2.980

3.  The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver.

Authors:  Julia I-Ju Leu; Maureen E Murphy; Donna L George
Journal:  J Liver       Date:  2013

Review 4.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

5.  Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model.

Authors:  Gregory A Azzam; Amanda K Frank; Monica Hollstein; Maureen E Murphy
Journal:  Cell Cycle       Date:  2011-05-01       Impact factor: 4.534

6.  Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes.

Authors:  Che-Pei Kung; Sakina Khaku; Matthew Jennis; Yan Zhou; Maureen E Murphy
Journal:  Mol Cancer Res       Date:  2014-09-25       Impact factor: 5.852

Review 7.  Illuminating p53 function in cancer with genetically engineered mouse models.

Authors:  Patty B Garcia; Laura D Attardi
Journal:  Semin Cell Dev Biol       Date:  2014-01-03       Impact factor: 7.727

8.  Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.

Authors:  Ahsan S Farooqi; Rebecca A Dagg; L Mi Rim Choi; Jerry W Shay; C Patrick Reynolds; Loretta M S Lau
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

9.  The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation.

Authors:  Amanda K Frank; Julia I-Ju Leu; Yan Zhou; Karthik Devarajan; Tatiana Nedelko; Andres Klein-Szanto; Monica Hollstein; Maureen E Murphy
Journal:  Mol Cell Biol       Date:  2011-01-18       Impact factor: 4.272

10.  Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.

Authors:  Maral Jamshidi; Marjanka K Schmidt; Thilo Dörk; Montserrat Garcia-Closas; Tuomas Heikkinen; Sten Cornelissen; Alexandra J van den Broek; Peter Schürmann; Andreas Meyer; Tjoung-Won Park-Simon; Jonine Figueroa; Mark Sherman; Jolanta Lissowska; Garrett Teoh Hor Keong; Astrid Irwanto; Marko Laakso; Sampsa Hautaniemi; Kristiina Aittomäki; Carl Blomqvist; Jianjun Liu; Heli Nevanlinna
Journal:  Int J Cancer       Date:  2012-10-25       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.